INTRODUCTION
Hematopoietic cell transplant (HCT)-associated thrombotic microangiopathy (TA-TMA) offers diagnostic and therapeutic challenges, and is associated with a high mortality rate and long-term complications in survivors. 1 The exact pathophysiology is unclear although endothelial injury may represent the final common pathway. [2] [3] [4] The use of high-dose chemotherapy, radiation therapy, unrelated donor, HLA-mismatched donor, exposure to calcineurin inhibitor (CNI), GvHD and infections are some of the important risk factors. [4] [5] [6] [7] [8] Similarly, GvHD, CMV viremia, liver dysfunction and significant gastric bleeding are some of the prognostic factors for TA-TMA. 8 Manifestations of TA-TMA may include thrombocytopenia, Coombs-negative microangiopathic hemolysis, schistocytes on peripheral blood smear, acute renal failure, mental status changes, pulmonary complications such as severe pulmonary arterial hypertension, and dysfunction of other organs causing multi-organ failure. [9] [10] [11] Such manifestations may be seen in patients with other HCT-related complications including GvHD, sepsis and CMV infection. Consequently, the diagnosis is difficult despite the availability of consensus criteria established by the Blood and Marrow Transplant Clinical Trials Network or other groups. 1 As the underlying mechanism for TA-TMA is complex and not well understood, the management options are unclear. 4, 11, 12 Currently available therapeutic options include withdrawal of CNIs, possible small role of therapeutic plasma exchange, rituximab and more recently eculizumab. Given the rarity of TA-TMA and limited high-quality data, more questions and fewer answers are available. In fact, the authors have met experts who have even raised skepticism regarding whether TA-TMA is a 'distinct diagnosis' or just a manifestation of other problems such as GvHD, sepsis, CMV viremia or graft failure in a sick transplant recipient. As vascular endothelium is a target of GvHD, TA-TMA has been regarded by some as a manifestation of acute endothelial GvHD. 13 Future prospective studies should consider this possibility and take into consideration other comorbidities to develop diagnostic tools and therapeutic approaches. Despite such limitations, we have attempted to present a focused review on the potential role of complement activation in the pathogenesis of TA-TMA and complement blockade as an emerging therapeutic strategy.
TRADITIONAL MANAGEMENT APPROACH
Change in immunosuppressive treatment with discontinuation of CNI, dose reduction or conversion to another drug is the initial therapy for most cases of CNI-related TA-TMA (Figure 1) . 14, 15 This approach may be particularly successful if TA-TMA is not severe and detected early on. Although patients may be closely monitored with assessment of clinical status, hemolytic parameters and organ function to capture disease worsening, a lack of formal grading to assess the severity of TA-TMA at suspicion may make it hard for a clinician to decide on a more conservative versus aggressive management strategy. Worel et al. 16 reported a response rate of 64% with treatment strategy combining withdrawal of CNI, daily plasma exchange until hematologic response was achieved and added the use of steroid in the presence of GvHD, however, the severity of TA-TMA at diagnosis and survival data are not mentioned. The risk of GvHD with discontinuation of CNI requires initiation of alternate immunosuppressant such as mycophenolate mofetil and prednisone. 14, 17 If the patient responds to manipulation of immunosuppressants, monitoring for worsening signs of TA-TMA and development of GvHD without further interventions may suffice.
Some studies have reported successful use of cyclosporine in tacrolimus-associated TA-TMA, although the reverse may not be as successful. [18] [19] [20] [21] [22] Replacing CNI with sirolimus is an unclear strategy as sirolimus is also associated with TA-TMA. In mild forms of TA-TMA, where discontinuation of the CNI is not feasible, some patients may possibly respond to dose reduction only. 23, 24 However, replacing CNI with other immunosuppressive agents may be more beneficial than dose reduction only. 12, 25, 26 In this context, interleukin-2 receptor antagonists such as basiliximab and daclizumab have also shown benefits in patients with TA-TMA. 12, 27 However, these approaches are less well studied and cannot be routinely recommended.
Although plasma exchange has been used in the past to treat TA-TMA, a large number of reports and case series suggest that it has transient acute effects at best. [28] [29] [30] [31] [32] The role of plasma exchange in TA-TMA is limited unless perhaps a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) level is low with activity o10% (unlikely in TA-TMA) or Abs against complement factor H (CFH) are present. 15 Rituximab, used frequently in thrombotic thrombocytopenic purpura, has been used in patients with TA-TMA as monotherapy or in combination with plasma exchange. 10, [33] [34] [35] Exact mechanisms are unknown, but it is speculated to deplete CD20 + B-cell precursors, attenuate T-cell activation and reduce cytokine release. 36 In a few small studies, the response rate has been demonstrated in up to two-third of patients; however, literature is limited to case reports and series. • Figure 1 . Management of hematopoietic cell transplant-associated thrombotic microangiopathy. *Diagnosis may be established using available criteria put forward by the Blood and Marrow Transplant Clinical Trials Network or other groups. It is important to rule out other alternative diagnoses such as GvHD or sepsis. 1 y With regards to choosing eculizumab versus rituximab, no studies have compared the efficacy of the two drugs. Although the mechanism of action is unclear, rituximab has shown to be effective in up to two-third of patients in a few small studies. 1 Rituximab is cheaper and may be more easily available in many centers. Oncologists and oncology pharmacists may be more familiar with rituximab than eculizumab. Hence, unless further studies are available, the choices of therapy are more based on drug availability and center preference. Eculizumab may be preferred if complement dysregulation is confirmed in a patient or in high-risk patients who present with proteinuria and elevated sC5b-9 at the time of TA-TMA diagnosis.
z The efficacy of these agents as a second-line therapy has to be tested in future studies.
alternative complement pathway activation have been implicated. The classic pathway may be activated by triggers including GvHD, high-dose chemotherapy and viral infections, leading to direct endothelial damage. 37 Low C4 levels and C4d staining of affected tissue may indicate classic pathway activation in TA-TMA. [38] [39] [40] Alternative pathway activation may result in the formation of CFH Abs. CFH Abs may be formed secondary to defective or absent CFHR1 protein leading to defects in CFHR3-CFHR1 genes, or owing to immune dysregulation after HCT. 41 The presence of CFH Abs may explain the response of TA-TMA to rituximab and plasma exchange, possibly through neutralization of CFH Ab activity. Formation of CFH Ab causes uninhibited formation of the C3 convertase, C3bBb on the surface of endothelial cells, which in turn forms additional molecules of C3b (the activated form of C3) leading to a complex C3bBb•C3b. C3bBb•C3b cleaves C5 into C5a and C5b, and promotes formation of lytic complex C5b-9 and the potent anaphylatoxin C5a, which causes injury to the endothelial cell and ultimately the characteristic findings of TMA. 42 Dysregulation in either the classic or alternative pathway finally results in the formation of terminal complement complex. In one study, patients with TA-TMA, with elevated markers of terminal complement activation (soluble terminal complement complex (sC5-9)) and proteinuria were associated with poor survival (o 20%); 43 this finding needs confirmation in the future studies.
'COMPLEMENT-CENTRIC DIAGNOSTIC STRATEGY'
The ability to determine activation of the complement pathway may possibly support diagnosis, guide therapy, and further disease understanding and drug development in TA-TMA. However, their utility in clinical practice is limited because of the lack of larger confirmatory studies, lack of standardization of technique and normal reference values, as well as limited availability of such tests. A multitude of quantitative, functional and genetic tests have been developed to capture complement activation. Quantitative tests include measurement of serum complement levels and CFH Ab. Although not sensitive and specific, low levels of C3 and increased levels of C5a and C5b-9 complex may be observed, as in patients with atypical hemolytic uremic syndrome (aHUS). 44 Functional assays include determination of total complement hemolytic activity (CH50), sC5b-9 and Bb. An in vitro functional complement assay, useful in diagnosing and monitoring treatment in aHUS, utilizes patient's serum to induce endothelial C5b-9 deposits on human microvascular endothelial cells. Treatment with eculizumab has been found to normalize the deposition. 45 Studies utilizing such a technique in TA-TMA may have important implications. Focal deposition of C3, C3d, C4d and C5b-9 in tissue biopsies such as kidney and skin have also been reported, and if confirmed, may emerge as a quick and useful diagnostic aid. 15 In fact, severe multi-organ damage, low C4 levels and C4d staining of affected tissue such as renal arterioles may be used as evidence of classic pathway activation. [38] [39] [40] Moreover, C4d staining has been observed in a few TA-TMA cases developing after HCT or after solid organ transplants. 40 If kidney biopsy is performed, C4d staining along with clinical signs may be used to support the diagnosis of TA-TMA, however, C4d deposition is not specific to TA-TMA. 40, 46 Mutation of one of the complement genes such as C3, CFB, CFH, CFHR1, CFHR3, CFHR5 and CFI may provide evidence of genetic susceptibilities to develop TA-TMA, 42 however, such a finding needs verification. It is also not clear if the test should be performed using recipient or donor DNA. A study by Jodele et al., 47 using recipients' blood before transplantation, has revealed differences in susceptibilities to TA-TMA based on the recipient genotype. Heterozygous CFHR3-CFHR1 deletions have been reported in HCT recipients with TMA in a study. Such genetic variations may be associated with CFH Abs. 41 Thus, chromosomal mutational analysis might be of research interest in testing the recipients' susceptibility to TA-TMA in the future. These findings are certainly exciting, but not ready for use in clinical practice yet.
COMPLEMENT BLOCKADE, AN ACCEPTABLE THERAPEUTIC STRATEGY?
Eculizumab, a monoclonal Ab against complement protein C5, prevents formation of membrane attack complex and complement activation. 48 It may be an option if initial therapy with discontinuation of CNI does not improve the disease process and in patients with severe disease manifestation. 1 Jodele et al. 49 have proposed that eculizumab may be started without stopping CNIs in some cases to avoid the risk of worsening of GvHD, however, this approach requires prospective evaluation taking into consideration the safety and cost-effectiveness of such an approach, and a possibility that GvHD may masquerade the manifestations of TA-TMA. Although significantly limited because of the quality of reported studies, a 2015 review of reported use of eculizumab in TMA associated with HCT or solid organ transplant demonstrated that 24 (92%) out of 26 patients were alive at 1-year follow-up, and the remaining 2 pediatric patients (8%) died. 50 Although this outcome appears impressive, experience of others is much less enthusiastic. In a more recent report, 12 patients with severe TA-TMA with neurological and/or renal involvement had an hematological response, and an overall survival of 50% and 33%, respectively at a median follow-up of 14 months. 51 The major cause of deaths in the patients were bacterial or fungal infection, acute GvHD, relapse of underlying malignancy and central nervous system complications. Vasu et al. 52 reported five patients treated with eculizumab, of which four demonstrated improvement in hematologic and renal parameters, but two succumbed to methicillin-resistant Staphylococcus aureus sepsis and Pseudomonas sepsis. Three different case reports describe three patients responding to the use of eculizumab, although two of them died after initial response. [53] [54] [55] The causes of death were acute respiratory distress syndrome of unknown cause 53 and diffuse alveolar hemorrhage. 55 Larger prospective trials are needed to confirm the value of eculizumab in TA-TMA.
At the present time, eculizumab-use may result in a hematologic response in TA-TMA; however, the efficacy may be less in sick patients with severe manifestations and other comorbidities, and hematologic response does not guarantee survival. Close monitoring of other complications including GvHD and aggressive infection prophylaxis may improve the outcomes associated with the use of eculizumab in TA-TMA. It has been suggested that prompt initiation of eculizumab should be carried out in high-risk patients who present with proteinuria and elevated sC5b-9 at the time of TA-TMA diagnosis, 42 however, many may recommend awaiting for a confirmation of such strategy. As eculizumab therapy is associated with increased susceptibility to meningococcal infection and infections with other encapsulated organisms, meningococcal vaccine or antibiotic prophylaxis with ciprofloxacin or penicillin V is advised. 48, [56] [57] [58] In HCT recipients with TMA, the response to meningococcal vaccination, however, may be poor.
Eculizumab dosing in TA-TMA is also not established and empirically follows the dosing schedule for aHUS. 59 Induction phase (900 mg weekly) for 4 weeks is followed by maintenance phase (1200 mg for first week, then 1200 mg every 2 weeks). Additional 300 mg or 600 mg may be administered within 1 h after plasma exchange. 59 The dosage in children may depend on weight and ranges from 300 mg for 5-10 kg to 900 mg for 40 kg or more. CH50 level, a hemolytic complement assay, has been proposed by Jodele et al. 37 to titrate eculizumab doses as drug monitoring is not readily available. The duration of treatment with eculizumab for TA-TMA is still uncertain, but unlike aHUS, it may be stopped after resolution of clinical symptoms and laboratory manifestations. 50 If future studies confirm, functional assay to determine resolution of complement activation may be useful to guide duration of therapy. In particular, the ability of patient's serum to induce endothelial C5b-9 deposits on human microvascular endothelial cells, or lack thereof after therapy with eculizumab, may be utilized to decide cessation of therapy. 44 At the present time, the use of eculizumab is still empirical, but reasonable, given a lack of good treatment option, however, monitoring and management of other complications have an equal or arguably more important role.
FUTURE PERSPECTIVE
Inhibitors of factor D are effective against paroxysmal nocturnal hemoglobinuria and aHUS in vitro. Factor D is a serine-specific protease that cleaves factor B, the rate-limiting step of alternative complement pathway. 60 Oral inhibitors of factor D may have a role in TA-TMA because of their specific alternative complement pathway blocking activity, and requires further studies. Similarly, there is an ongoing phase II trial of a novel drug, OMS721 in patients with aHUS, TA-TMA and refractory thrombotic thrombocytopenic purpura (ClinicalTrials.gov ID NCT02222545). OMS721 is a human monoclonal Ab, which selectively inhibits mannan-binding lectin-associated serine protease-2, a pro-inflammatory protein target in the lectin pathway in complement system. The serine protease inhibitors (serpins) such as C1-inhibitor and antithrombin, and Kunitz-type inhibitors such as aprotinin and tissue factor pathway inhibitor, are other mannan-binding lectin-associated serine protease-2 inhibitors with potential utility in TA-TMA. 61 Other complement inhibitors such as compastatin analogs prevent the conversion of C3 to C3b, thus, impairing the initiation, amplification and terminal activation of complement pathways. 62 Unlike eculizumab, these drugs act upstream in complement pathway, and have been shown to prevent hemolysis and opsonization of paroxysmal nocturnal hemoglobinuria erythrocytes in vitro. Similarly, TNT003, effective in treatment of cold agglutinin disease, is an inhibitor of serine protease C1s and prevents both C3b deposition as well as the formation of terminal complement complex. 63 These drugs inhibit the complement system and may hold promise in the management of various complement-mediated disorders including TA-TMA. The results of clinical trials will demonstrate if these agents can have a more important role than eculizumab.
Although therapeutic advances are clearly needed in TA-TMA, other important research areas include diagnostic strategies and understanding of the molecular pathogenesis of the disease process. Is TA-TMA a 'distinct diagnosis'? How do we diagnose TA-TMA in patients with other post-transplant complications such as GvHD or CMV infection? Is early detection and management of GvHD and other post-transplant complications more important to the survival of patients with TA-TMA than complement blockade?
CONCLUSION
The management of TA-TMA is suboptimal, and associated with significant morbidity and mortality. Discontinuation or dose reduction of CNI comprises the initial treatment, effective in some patients. Eculizumab prevents formation of terminal complement complex and has been used in TA-TMA, however, larger prospective trials are needed to confirm its value. A number of novel complement inhibitors are in the making and may change the treatment paradigm of TA-TMA in the future. However, patients may continue to die because of the associated complications such as infection, renal, cardiac or other organ toxicities, and GvHD. Hence, one of the key challenges in the future is going to be our ability to determine optimal strategies to prevent and manage such complications.
